BRD2 and breast carcinoma: Another study reported that E2 and FSH remained suppressed during 96 weeks of monthly or 3-monthly goserelin plus tamoxifen in premenopausal women with estrogen receptor-positive early breast cancer (Masuda et al., 2011).